Other Events ·
Quantum BioPharma corrects fractional share treatment under proposed share consolidation
QNTMQuantum Biopharma Ltd.
Quantum BioPharma Ltd. filed a supplement to its management information circular to clarify the treatment of fractional shares resulting from a proposed share consolidation. The correction specifies that fractions equal to or less than one-half of a share will be rounded down, while those greater than one-half will be rounded up. Additionally, the company clarified a measure to cap the aggregate voting power of multiple voting share holders at 70% if their ownership exceeds that threshold following the cancellation of subordinate voting shares. The annual general and special meeting to vote on these matters is scheduled for November 10, 2026. Quantum BioPharma Ltd. is a biopharmaceutical company developing innovative assets for neurodegenerative and metabolic disorders.